Answers are grounded in this paper and cite their sources.
Reports of microplastics and nanoplastics (MNPs) in human tissues and biological fluids have multiplied rapidly, spanning organ systems that were not previously thought accessible to environmental particulates. The literature is heterogeneous in analytical method, contamination control and reporting unit, which makes the body of evidence difficult to interpret as a whole. We set out to map where MNPs have been reported in the human body, by which methods, and how robustly those reports are supported. We conducted a scoping review following the Joanna Briggs Institute methodology and the PRISMA extension for Scoping Reviews (PRISMA-ScR), using a Population–Concept–Context framework. PubMed, Web of Science and Scopus were searched, with the last search run on 1 January 2026, for primary studies reporting chemically or spectroscopically confirmed MNP detection in human tissues or fluids. For each study we charted anatomical site, analytical approach, particle characteristics, and indicators relevant to evidence confidence (contamination-control protocol, procedural blanks, blank correction, polymer confirmation method and the size range accessible to the method). We included 110 studies published between 2021 and 2025, reporting MNPs across 13 organ systems; 50 examined solid tissues or surface samples only, 46 biological fluids or excreta only, and 14 both. The digestive and female reproductive systems were the most studied (30 studies each); the auditory, ocular, endocrine, lymphatic, musculoskeletal and integumentary systems were each addressed by three or fewer. Procedural blanks were reported in 102 studies (92.7%); explicit blank correction was reported in 23 (20.9%), although many studies reported no particles in their blanks. Seventy-three studies (66.4%) identified particles by spectroscopy only, 14 (12.7%) quantified polymer mass by thermal or chromatographic methods only, and 23 (20.9%) used both. In 51 studies (46.4%) particle identification relied on infrared methods with a lower size limit of roughly 10–20 μm. Reported detection spanned the brain, cerebrospinal fluid, placenta, amniotic fluid, bone marrow, vitreous humour and the intervertebral disc. Recurring observations were higher reported burdens in tumour than in comparison tissue in five cancer types (with no difference in lung adenocarcinoma), detection in compartments behind the blood–brain, blood–retinal and placental barriers, and detection in samples from early gestation through infancy. Detection rates, particle sizes and concentrations varied substantially with analytical method. Several reported mass concentrations, particularly in brain tissue, are difficult to reconcile with what is known about particle uptake and translocation and require independent verification. MNPs have been reported in most human organ systems examined, but the evidence is uneven: several systems rest on one to three studies, blank correction is uncommon, and reported sizes and concentrations are strongly influenced by the analytical method used. The observed associations with disease are cross-sectional; they generate hypotheses and do not establish cause. The field’s priority is standardised, contamination-controlled and fully reported measurement, together with longitudinal and mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: